Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

3SBio Given SFDA Permission for Phase III Trial of Anti-Rejection Drug

publication date: Jun 28, 2012
3SBio received permission from the SFDA to conduct the China arm of the multi-national Phase III trial of voclosporin, a new generation calcineurin inhibitor. 3SBio in-licensed the drug from Isotechnika Pharma of Canada in 2010. The drug suppresses immune system activity and will be tested in patients undergoing renal transplants. More details...

Stock Symbols: (NSDQ: SSRX) (TSX: ISA)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event

Device China 2018
September 8-9, 2018